Overview
Alpha-dystroglycanopathy (also called dystroglycanopathy or alpha-DG deficiency) is a group of rare inherited muscle diseases caused by problems with a protein called alpha-dystroglycan. This protein acts like a glue that holds muscle cells and brain cells together and connected to their surroundings. When alpha-dystroglycan does not work properly — either because there is not enough of it or because it is not built correctly — muscles and the brain can be seriously affected. The disease belongs to a broader family called congenital muscular dystrophies. It can range from very severe forms present at birth, where babies have very weak muscles and serious brain problems, to milder forms that appear in childhood or even adulthood with mainly muscle weakness. Common symptoms include muscle weakness, difficulty walking, intellectual disability, eye problems, and in severe cases, brain malformations. The heart and breathing muscles can also be affected in some people. There is currently no cure for alpha-dystroglycanopathy. Treatment focuses on managing symptoms, supporting breathing and heart function, physical and occupational therapy, and helping with learning and development. A team of specialists is usually needed to provide the best care. Research into gene therapy and other targeted treatments is ongoing, giving hope for future options.
Also known as:
Key symptoms:
Muscle weakness, especially in the arms and legsDifficulty walking or inability to walkDelayed motor milestones such as late sitting or standingIntellectual disability or learning difficultiesBrain malformations visible on MRI scansEye problems including poor vision or structural eye abnormalitiesSeizures or epilepsyBreathing difficulties due to weak respiratory musclesHeart muscle problems (cardiomyopathy)Very low muscle tone (floppiness) in babiesContractures — stiff joints that do not move fullyFeeding difficulties in infantsElevated creatine kinase (CK) levels in the blood, a sign of muscle damage
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Qualitative or quantitative defects of alpha-dystroglycan.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Qualitative or quantitative defects of alpha-dystroglycan at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Qualitative or quantitative defects of alpha-dystroglycan.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Qualitative or quantitative defects of alpha-dystroglycan.
Community
No community posts yet. Be the first to share your experience with Qualitative or quantitative defects of alpha-dystroglycan.
Start the conversation →Latest news about Qualitative or quantitative defects of alpha-dystroglycan
No recent news articles for Qualitative or quantitative defects of alpha-dystroglycan.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which specific gene is causing my (or my child's) condition, and what does that mean for the expected disease course?,What specialists should be part of our care team, and how often should we see each one?,Are there any clinical trials or research studies we might be eligible for?,What signs should prompt us to go to the emergency room immediately?,What respiratory and cardiac monitoring do you recommend, and how often?,Are other family members at risk, and should they be tested?,What support services — such as physical therapy, special education, or home care — should we be accessing?
Common questions about Qualitative or quantitative defects of alpha-dystroglycan
What is Qualitative or quantitative defects of alpha-dystroglycan?
Alpha-dystroglycanopathy (also called dystroglycanopathy or alpha-DG deficiency) is a group of rare inherited muscle diseases caused by problems with a protein called alpha-dystroglycan. This protein acts like a glue that holds muscle cells and brain cells together and connected to their surroundings. When alpha-dystroglycan does not work properly — either because there is not enough of it or because it is not built correctly — muscles and the brain can be seriously affected. The disease belongs to a broader family called congenital muscular dystrophies. It can range from very severe forms pr
How is Qualitative or quantitative defects of alpha-dystroglycan inherited?
Qualitative or quantitative defects of alpha-dystroglycan follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.